AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9213839 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 1530319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy (I.A.)
Number of subjects: 70
Study 1530319 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (I.V.)
Number of subjects: 70
Study 4018470 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN; 40 mg orally)
Number of subjects: 18
Study 4018470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release Isosorbide dinitrate (SRDI; 40 mg orally)
Number of subjects: 18
Study 30797848 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-0 Fast Absorbing Gut (FG)
Number of subjects: 0
Study 30797848 — intervention group
Group type: COMPARATOR
Intervention: 5-0 Fast Absorbing Gut (FG)
Number of subjects: 0
Study 29076978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 75
Study 29076978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 28708766 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo with rationale (OPR)
Number of subjects: 160
Study 28708766 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive placebos (DP)
Number of subjects: 160
Study 28708766 — intervention group
Group type: COMPARATOR
Intervention: Open-label placebo without rationale (OPR‐)
Number of subjects: 160
Study 28708766 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 160
Study 25748442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐MTHF (5 mM) administered locally via intradermal microdialysis in older adults.
Number of subjects: 22
Study 25748442 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) supplementation for 6 weeks in older adults.
Number of subjects: 22
Study 25748442 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for 6 weeks in older adults.
Number of subjects: 22
Study 23863960 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEAR regimen (oral levofloxacin, ethambutol, azithromycin, and rifampin)
Number of subjects: 30
Study 23863960 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 30
Study 20886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-capacity forceps (2.2-mm forceps, Radial jaw3)
Number of subjects: 32
Study 20886402 — intervention group
Group type: COMPARATOR
Intervention: Standard forceps (1.8-mm forceps, FB-39Q)
Number of subjects: 32
Study 19121185 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell volume-based transfusion guideline (group RCV)
Number of subjects: 86
Study 19121185 — intervention group
Group type: COMPARATOR
Intervention: Standard haemoglobin concentration-based departmental policy (group C)
Number of subjects: 86
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of drug treatment
Number of subjects: 153
Study 15979246 — intervention group
Group type: COMPARATOR
Intervention: No history of drug treatment
Number of subjects: 153
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving drugs at least 15 days in the past month
Number of subjects: 153
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: Using cocaine at least 15 days in the past month
Number of subjects: 153
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: ASI alcohol composite score
Number of subjects: 153
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived seriousness of legal problems
Number of subjects: 153
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: History of at least 3 pregnancies
Number of subjects: 153
Study 15979246 — intervention group
Group type: EXPERIMENTAL
Intervention: History of physical abuse by a known person
Number of subjects: 153
Study 14588178 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lung biopsy
Number of subjects: 100
Study 14588178 — intervention group
Group type: COMPARATOR
Intervention: Open lung biopsy
Number of subjects: 100
Study 10672720 — intervention group
Group type: EXPERIMENTAL
Intervention: Forlax (Beaufour Ipsen, France)
Number of subjects: 0
Study 8839602 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive, hypervolemic, hemodilutional therapy (HT)
Number of subjects: 0
Study 8839602 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1750429 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide-containing antacid (113 mg per tablet, 2 tablets four times daily)
Number of subjects: 56
Study 1750429 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 56
Study 1750429 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide-containing antacid
Number of subjects: 56
Study 6976617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin), 3000 mg daily
Number of subjects: 12
Study 6976617 — intervention group
Group type: COMPARATOR
Intervention: Fluproquazone, 300 mg daily
Number of subjects: 12
Study 31537110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasalance-based preclassification of oral-nasal balance disorders
Number of subjects: 54
Study 31778601 — intervention group
Group type: EXPERIMENTAL
Intervention: esomeprazole (40 mg/d)
Number of subjects: 160
Study 31778601 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine (40 mg/d)
Number of subjects: 160
Study 28653499 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) intervention
Number of subjects: 1635
Study 28653499 — intervention group
Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 1635
Study 26380271 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based mental health programme (20 hours total, 1 hour per week)
Number of subjects: 308
Study 26380271 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 classrooms)
Number of subjects: 308
Study 22588377 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Cat program (cognitive-behavioral therapy; CBT)
Number of subjects: 22
Study 22588377 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 22
Study 22092484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin trial (Vitamin C = 500 mg/day + Vitamin E = 100 IU/day)
Number of subjects: 9
Study 22092484 — intervention group
Group type: COMPARATOR
Intervention: Placebo trial
Number of subjects: 9
Study 18852497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 9
Study 18852497 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring as a form of therapy
Number of subjects: 9
Study 18852497 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 9
Study 16446018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized knee-bends
Number of subjects: 17
Study 16446018 — intervention group
Group type: COMPARATOR
Intervention: Unconstrained conditions
Number of subjects: 17
Study 15244203 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil/midazolam (n=18)
Number of subjects: 26
Study 15244203 — intervention group
Group type: COMPARATOR
Intervention: tramadol/midazolam (n=18)
Number of subjects: 26
Study 15244203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (remifentanil/midazolam and tramadol/midazolam)
Number of subjects: 26
Study 10831016 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 193
Study 10831016 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg
Number of subjects: 193
Study 10831016 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg
Number of subjects: 193
Study 10831016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 15900669 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructions with wide interdental spaces
Number of subjects: 21
Study 15900669 — intervention group
Group type: COMPARATOR
Intervention: Constructions with minimized interdental spaces
Number of subjects: 21
Study 15900669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (wide and minimized interdental spaces)
Number of subjects: 21
Study 3964334 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg t.i.d. indometacin
Number of subjects: 16
Study 3964334 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg t.i.d. acemetacin
Number of subjects: 16
Study 29787532 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention focusing on symptom education, coping strategies, and utilizing supports
Number of subjects: 0
Study 29787532 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 3-minute educational brochure review
Number of subjects: 0
Study 27818598 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge aspiration needle (AN)
Number of subjects: 56
Study 27818598 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge core biopsy needle (PC)
Number of subjects: 56
Study 24408976 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 469
Study 24408976 — intervention group
Group type: COMPARATOR
Intervention: Progressive addition lenses
Number of subjects: 469
Study 22773263 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot training + Physiotherapy (30 min each for 60 min sessions, 5 days a week for 4 weeks)
Number of subjects: 30
Study 22773263 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (60 min sessions, 5 days a week for 4 weeks)
Number of subjects: 30
Study 22773263 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot training + Physiotherapy
Number of subjects: 30
Study 22773263 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 30
Study 20082132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode array ablation catheters with uninterrupted warfarin
Number of subjects: 81
Study 20082132 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted aspirin
Number of subjects: 81
Study 18756743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (Preductal MR) in addition to traditional therapy
Number of subjects: 0
Study 18756743 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 0
Study 18756743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (Preductal MR)
Number of subjects: 0
Study 16385010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality trials with methods such as concealment of allocation, blinding, and outcome assessment
Number of subjects: 0
Study 16385010 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate funding, good infrastructure, and networks
Number of subjects: 0
Study 11805921 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg daily for 5 consecutive days starting 3 days before surgery
Number of subjects: 100
Study 11805921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10715762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 124
Study 10715762 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 124
Study 10715762 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine throat spray only
Number of subjects: 124
Study 8868980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 2.5 mg daily
Number of subjects: 317
Study 8868980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg daily
Number of subjects: 317
Study 8868980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 1595521 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil (600 mg/day orally for 1 week before PTCA and for 4 to 6 months after PTCA)
Number of subjects: 72
Study 1595521 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg/day) and dipyridamole (150 mg/day)
Number of subjects: 72
Study 6705164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (2 mg/hr iv, preceded by a 10 mg bolus in three patients)
Number of subjects: 5
Study 6705164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6705164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 5
Study 31339808 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (Word Discovery)
Number of subjects: 78
Study 31339808 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching practice
Number of subjects: 78
Study 31339808 — intervention group
Group type: COMPARATOR
Intervention: No intervention words
Number of subjects: 78
Study 30145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote delivery (RD) using video conferencing on a tablet computer
Number of subjects: 120
Study 30145269 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FTF) visits
Number of subjects: 120
Study 30145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote delivery (RD)
Number of subjects: 120
Study 30145269 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FTF)
Number of subjects: 120
Study 30145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote delivery (RD) and Face-to-face (FTF)
Number of subjects: 120
Study 26754679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg
Number of subjects: 72
Study 26754679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 20 mg
Number of subjects: 72
Study 26754679 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 72
Study 26754679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24802413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor therapy
Number of subjects: 449
Study 24802413 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline poor sleep quality
Number of subjects: 449
Study 24802413 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tired feeling
Number of subjects: 449
Study 24802413 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline forgetfulness
Number of subjects: 449
Study 24802413 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of baseline symptoms (3 to 5 symptoms vs 0 to 2 symptoms)
Number of subjects: 449
Study 22475889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 or 10 mg/day
Number of subjects: 687
Study 22475889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 or 10 mg/day (stable responders)
Number of subjects: 687
Study 22475889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 22475889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Number of subjects: 687
Study 22475889 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label Lu AA21004
Number of subjects: 687
Study 20444957 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol therapy
Number of subjects: 113
Study 20444957 — intervention group
Group type: COMPARATOR
Intervention: Plant sterol therapy in mice
Number of subjects: 113
Study 19235402 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor trail-making task
Number of subjects: 54
Study 19235402 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task
Number of subjects: 54
Study 19235402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility task
Number of subjects: 54
Study 16231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy
Number of subjects: 757
Study 16231850 — intervention group
Group type: EXPERIMENTAL
Intervention: In-field radiation therapy (RT)
Number of subjects: 757
Study 16231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation and cisplatin- and MOPP-containing therapies
Number of subjects: 757
Study 12031749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV
Number of subjects: 100
Study 12031749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10071983 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP16) at various dose regimens (30 to 200 mg, infusion times 0.5 to 2 h)
Number of subjects: 34
Study 7985891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid procollagen III levels
Number of subjects: 117
Study 7985891 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen III levels of 1.75 U/mL or more on day 3
Number of subjects: 117
Study 7985891 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen III levels of 1.75 U/mL or more on day 7
Number of subjects: 117
Study 7985891 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen III levels of 1.75 U/mL or more on day 14
Number of subjects: 117
Study 7985891 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fatality rate in patients with ARDS
Number of subjects: 117
Study 1665493 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF 250 micrograms/m2 s.c. on days 4-12
Number of subjects: 30
Study 1665493 — intervention group
Group type: COMPARATOR
Intervention: No GM-CSF
Number of subjects: 30
Study 1665493 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF starting on day 1
Number of subjects: 30
Study 1665493 — intervention group
Group type: EXPERIMENTAL
Intervention: AIO chemotherapy (A, 50 mg/m2 on day 1; I, 2 g/m2 on days 1-3; O, 2 mg on day 1) alternating with cisplatin (90 mg/m2 on day 1) and etoposide (150 mg/m2 on days 1-3)
Number of subjects: 30
Study 1665493 — intervention group
Group type: EXPERIMENTAL
Intervention: AIO chemotherapy (A, Adriamycin 25 mg/m2 on days 1 + 2; I, ifosfamide 2 g/m2 on days 1-5; O, vincristine 2 mg on day 1)
Number of subjects: 30
Study 1665493 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 30
Study 6851037 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. atenolol followed by oral treatment for 10 days
Number of subjects: 477
Study 6851037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 477
Study 30926371 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oral immunotherapy
Number of subjects: 73
Study 30926371 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation and strict dietary exclusion)
Number of subjects: 73
Study 30037426 — intervention group
Group type: EXPERIMENTAL
Intervention: High TTR (≥70%)
Number of subjects: 1067
Study 30037426 — intervention group
Group type: COMPARATOR
Intervention: NYHA class III and/or IV
Number of subjects: 1067
Study 30037426 — intervention group
Group type: COMPARATOR
Intervention: Each 10-point increase in MLWHF score
Number of subjects: 1067
Study 30037426 — intervention group
Group type: COMPARATOR
Intervention: Higher number of HF hospitalizations per year
Number of subjects: 1067
Study 27618825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 106
Study 27618825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 24535791 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (levobupivacaine) with 20 mL 0.25% levobupivacaine and 40 mg methylprednisolone
Number of subjects: 60
Study 24535791 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (bupivacaine) with 20 mL 0.25% bupivacaine and 40 mg methylprednisolone
Number of subjects: 60
Study 24535791 — intervention group
Group type: COMPARATOR
Intervention: Group C (control) with 20 mL physiological saline
Number of subjects: 60
Study 22334121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Δ⁹-THC (0.015 mg/kg)
Number of subjects: 26
Study 22334121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Δ⁹-THC (0.03 mg/kg)
Number of subjects: 26
Study 22334121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19581560 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 45
Study 19581560 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study 17932908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa 9 million IU 3 times a week
Number of subjects: 492
Study 17932908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 9 million IU daily
Number of subjects: 492
Study 17932908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine treatments (interferon-alfa and interleukin-2)
Number of subjects: 492
Study 17932908 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 200 mg daily
Number of subjects: 492
Study 15804733 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg
Number of subjects: 90
Study 15804733 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 90
Study 15804733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12414028 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-jejunal enteral feeding
Number of subjects: 40
Study 12414028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous crystalloid fluids
Number of subjects: 40
Study 10788904 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based educational self-management program for children with asthma
Number of subjects: 0
Study 7832962 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 0
Study 7832962 — intervention group
Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 0
Study 1983780 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 (50 mg)
Number of subjects: 51
Study 1983780 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (2 mg)
Number of subjects: 51
Study 1983780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP)
Number of subjects: 28
Study 7191779 — intervention group
Group type: COMPARATOR
Intervention: Pyrazofurin
Number of subjects: 28
Study 31699176 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconscious Version of the Family Decision-Making Self-Efficacy Scale (FDMSE)
Number of subjects: 215
Study 30343508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (40 mg, single daily dose)
Number of subjects: 31
Study 30343508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg t.i.d.)
Number of subjects: 31
Study 30343508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (sildenafil and tadalafil)
Number of subjects: 31